Clinical summary
Summary
This study has 5 experimental arms across two phases. In Parts 1A and 1B, participants will receive BMS-986253 and nivolumab. In Part 1C, participants will receive BMS-986253 in combination with nivolumab and ipilimumab. In Part 2A, participants will receive BMS-986253 in combination with nivolumab and ipilimumab. In Part 2B, participants will receive a placebo in combination with nivolumab and ipilimumab.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Bristol-Myers Squibb (BMS)
Scientific Title
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers